CLASS II Drug recall · Reported 19 Jul 2017 · FDA Enforcement Report
5% Dextrose Injection, USP Viaflex recalled by Baxter Healthcare
Baxter Healthcare is recalling 5% Dextrose Injection, USP Viaflex, distributed nationwide in the US. The recall was initiated on 6 Jul 2017 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0972-2017
- FDA event ID
- 77676
- Recalling firm
- Baxter Healthcare, Deerfield, IL
- Brand
- Dextrose
- Manufacturer
- Baxter Healthcare Corporation
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 6 Jul 2017
- FDA classified
- 11 Jul 2017
- Reported
- 19 Jul 2017
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Foreign Material
- Drug class
- Injectable & IV Drugs
Timeline
| 6 Jul 2017 | Recall initiated by company | |
| 11 Jul 2017 | Classified by FDA | +5 days |
| 19 Jul 2017 | Published in enforcement report | +8 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of Assurance of Sterility: Bags have the potential to leak.
Foreign material recalls cover pieces of metal, plastic, glass, wood or other objects that got into the product during processing and could cause injury if eaten.
Product as listed by the FDA
5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Rx only, Baxter Healthcare Corporation, Deerfield IL 60015 USA, Product Code: 2B0089, NDC: 0338-0017-38
Where it was distributed
Nationwide, Puerto Rico and Saudi Arabia
Questions about this recall
Is 5% Dextrose Injection, USP Viaflex recalled?
Yes. Baxter Healthcare recalled 5% Dextrose Injection, USP Viaflex on 6 Jul 2017. The recall is Class II and its status is Terminated. Recall number D-0972-2017.
Why was it recalled?
Lack of Assurance of Sterility: Bags have the potential to leak.
Which lots are affected?
Lot: P361618, Exp 09/30/18;
Where was it sold?
Nationwide, Puerto Rico and Saudi Arabia
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from Baxter Healthcare
All 564| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS I | Dextrose Injection, USP, 70 % recalled by Baxter Healthcare | Baxter Healthcare | Particulate Matter | Nationwide |
| Drug | CLASS I | 9% Sodium Chloride Injection USP, Viaflex recalled by Baxter HealthcareSodium Chloride | Baxter Healthcare | Particulate Matter | IL |
| Device | CLASS II | Baxter Novum IQ Syringe Pump, Loaner recalled by Baxter Healthcare | Baxter Healthcare | Device Malfunction | Nationwide |
| Device | CLASS II | Baxter Novum IQ Syringe Pump recalled by Baxter Healthcare | Baxter Healthcare | Device Malfunction | Nationwide |
| Drug | CLASS II | Clindamycin Phosphate in 9% Sodium Chloride Injection recalledClindamycin Phosphate | Baxter Healthcare | Sterility | Nationwide |
Other Dextrose Monohydrate recalls
All 14| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | 5% Dextrose Injection, USP per (50 mg per mL) in a freeflex recalledDextrose | Fresenius Kabi USA | Sterility | Nationwide |
| Drug | CLASS II | 5% Dextrose Injection, USP per (50 mg per mL) in a freeflex recalledDextrose | Fresenius Kabi USA | Sterility | Nationwide |
| Drug | CLASS II | 5% Dextrose Injection, USP per (50 mg per mL) in a freeflex recalledDextrose | Fresenius Kabi USA | Sterility | Nationwide |
| Drug | CLASS II | 5% Dextrose Injection, USP ADD-Vantage Unit recalled by PfizerDextrose | Pfizer | Sterility | Nationwide |
| Drug | CLASS II | 25% Dextrose Injection, USP (250 mg/mL) Single-dose recalled by PfizerDextrose | Pfizer | Other | Nationwide |